Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081057 | 0.91 | CYP3A4 (0.53) | KMT2A | |
| SCHEMBL16628712 | 0.89 | ADORA3 (0.56) | APPNUDT1 | |
| SCHEMBL3090418 | 0.87 | SCD5 (0.52) | APPKMT2A | |
| SCHEMBL16628815 | 0.86 | ADORA3 (0.58) | APPTDP1KMT2A | |
| SCHEMBL13180096 | 0.86 | CYP3A4 (0.47) | APPNUDT1 | |
| SCHEMBL3089574 | 0.83 | MEN1 (0.52) | KMT2A | |
| SCHEMBL13144394 | 0.83 | KDM4E (0.48) | KMT2ANUDT1 | |
| SCHEMBL13144381 | 0.83 | ADORA3 (0.47) | — | |
| SCHEMBL16628732 | 0.81 | APP (0.52) | APPKMT2A | |
| SCHEMBL16628717 | 0.81 | LMNA (0.50) | TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | claimed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | APP 3605/4885TDP1 888/4885KMT2A 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.